ArticleProceedings of the National Academy of Sciences of the United States of America1992
Genomic structure of the human caldesmon gene.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 92 citations in OpenAlex.
- Glucocorticoid receptor-induced non-muscle caldesmon regulates metastasis in castration-resistant prostate cancer.Oncogenesis · 2023Article
- Immunohistochemical Expression Analysis of Caldesmon Isoforms in Colorectal Carcinoma Reveals Interesting Correlations with Tumor Characteristics.International journal of molecular sciences · 2023Article
- Emerging role of caldesmon in cancer: A potential biomarker for colorectal cancer and other cancers.World journal of gastrointestinal oncology · 2022Review
- CALD1 promotes the expression of PD-L1 in bladder cancer via the JAK/STAT signaling pathway.Annals of translational medicine · 2021Article
- Article
- Weighted Gene Co-expression Network Analysis Identifies CALD1 as a Biomarker Related to M2 Macrophages Infiltration in Stage III and IV Mismatch Repair-Proficient Colorectal Carcinoma.Frontiers in molecular biosciences · 2021Article
- Proteomic analysis of Medulloblastoma reveals functional biology with translational potential.Acta neuropathologica communications · 2018Article
- Overexpression of caldesmon is associated with tumor progression in patients with primary non-muscle-invasive bladder cancer.Oncotarget · 2015Article
- cGMP-dependent protein kinase Iβ regulates breast cancer cell migration and invasion via interaction with the actin/myosin-associated protein caldesmon.Journal of cell science · 2013Article
- Accumulation of splice variants and transcripts in response to PI3K inhibition in T cells.PloS one · 2013Article
- Up-regulated expression of l-caldesmon associated with malignancy of colorectal cancer.BMC cancer · 2012Article
- Detrimental effects of glucocorticoids on neuronal migration during brain development.Molecular psychiatry · 2009Article
- Glucocorticoid receptor-mediated expression of caldesmon regulates cell migration via the reorganization of the actin cytoskeleton.The Journal of biological chemistry · 2008Article
- Caldesmon as a therapeutic target for proliferative vascular diseases.Mini reviews in medicinal chemistry · 2008Review
- Caldesmon and the regulation of cytoskeletal functions.Advances in experimental medicine and biology · 2008Review
- Genetic ablation of zyxin causes Mena/VASP mislocalization, increased motility, and deficits in actin remodeling.The Journal of cell biology · 2006Article
- Differential expression of splicing variants of the human caldesmon gene (CALD1) in glioma neovascularization versus normal brain microvasculature.The American journal of pathology · 2004Article
- Probing the human natural autoantibody repertoire using an immunoscreening approach.Clinical and experimental immunology · 2000Article
- Caldesmon inhibits nonmuscle cell contractility and interferes with the formation of focal adhesions.Molecular biology of the cell · 1999Article
- Changes in the balance of phosphoinositide 3-kinase/protein kinase B (Akt) and the mitogen-activated protein kinases (ERK/p38MAPK) determine a phenotype of visceral and vascular smooth muscle cells.The Journal of cell biology · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The high molecular weight caldesmon (h-CaD) is predominantly expressed in smooth muscles, whereas the low molecular weight caldesmon (l-CaD) is widely distributed in nonmuscle tissues and cells. The changes in CaD isoform expression are closely correlated with the phenotypic modulation of smooth muscle cells. During a search for isoform diversity of human CaDs, l-CaD cDNAs were cloned from HeLa S3 cells. HeLa l-CaD I is composed of 558 amino acids, whereas 26 amino acids (residues 202-227 for HeLa l-CaD I) are deleted in HeLa l-CaD II. The short amino-terminal sequence of HeLa l-CaDs is different from that of fibroblast (WI-38) l-CaD II and human aorta h-CaD. We have also identified WI-38 l-CaD I, which contains a 26-amino acid insertion relative to WI-38 l-CaD II. To reveal the molecular events of the expressional regulation of the CaD isoforms, the genomic structure of the human CaD gene was determined. The human CaD gene is composed of 14 exons and was mapped to a single locus, 7q33-q34. The 26-amino acid insertion is encoded in exon 4 and is specifically spliced in the mRNAs for both h-CaD and l-CaDs I. Exon 3 is the exon that encodes the central repeating domain specific to h-CaD (residues 208-436) together with the common domain in all CaD (residues 73-207 for h-CaD and WI-38 l-CaDs, and residues 68-201 for HeLa l-CaDs). The regulation of h- and l-CaD expression is thought to depend on selection of the two 5' splice sites within exon 3. Thus, the change in expression between l-CaD and h-CaD might be caused by this splicing pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.